We investigated whether the prokinetic activity of mosapride , a 5-hydroxytryptamine 4 receptor agonist , in combination with proton pump inhibitor ( PPI ) would ameliorate symptoms of gastroesophageal reflux disease ( GERD ) in Japanese patients .